Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid
- PMID: 1846070
- DOI: 10.1016/0006-2952(91)90016-x
Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid
Abstract
Stimulation of lipolysis in murine adipocytes in response to a lipid-mobilizing factor produced by a cachexia-inducing murine adenocarcinoma was inhibited by eicosapentaenoic acid (EPA) with a Ki value of 104 microM. The inhibitory effect was strictly structurally specific, since other related fatty acids of both the (n-3) and (n-6) series were ineffective as inhibitors of the lipolytic process. Induction of lipolysis by both salbutamol and ACTH was also inhibited by EPA, suggesting that the effect is exerted on a step central to the process of lipolysis. Lipolysis induced with the tumour lipid-mobilizing factor was associated with a prolonged elevation of the intracellular level of cyclic AMP in adipocytes, in contrast with ACTH and salbutamol. The elevation of adipocyte cyclic AMP in response to the tumour lipid-mobilizing factor and lipolytic hormones was inhibited by EPA. In vivo, administration of pure EPA to weight losing mice bearing the MAC16 adenocarcinoma completely prevented weight loss and tumour growth rate. In contrast both the other (n-3) fatty acid present in fish oil, docosahexaenoic acid (DHA), and linoleic acid were ineffective in inhibiting weight loss or the growth of the MAC16 tumour. This suggests that inhibition of tumour lipolytic activity accounts for the anticachectic effect of EPA, and that a correlation may exist between the inhibition of cachexia and the inhibition of tumour growth.
Similar articles
-
Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia.Nutrition. 1996 Jan;12(1 Suppl):S31-3. doi: 10.1016/0899-9007(96)90015-5. Nutrition. 1996. PMID: 8850217
-
Mechanism of lipid mobilization associated with cancer cachexia: interaction between the polyunsaturated fatty acid, eicosapentaenoic acid, and inhibitory guanine nucleotide-regulatory protein.Prostaglandins Leukot Essent Fatty Acids. 1993 Jan;48(1):105-9. doi: 10.1016/0952-3278(93)90017-q. Prostaglandins Leukot Essent Fatty Acids. 1993. PMID: 8380931 Review.
-
Effect of eicosapentaenoic acid (EPA) on expression of a lipid mobilizing factor in adipose tissue in cancer cachexia.Prostaglandins Leukot Essent Fatty Acids. 2005 Jun;72(6):409-14. doi: 10.1016/j.plefa.2005.03.002. Prostaglandins Leukot Essent Fatty Acids. 2005. PMID: 15899583
-
Mechanism of inhibition of a tumor lipid-mobilizing factor by eicosapentaenoic acid.Cancer Res. 1998 Nov 1;58(21):4827-31. Cancer Res. 1998. PMID: 9809986
-
Pathogenesis of cancer cachexia.J Support Oncol. 2003 Sep-Oct;1(3):159-68. J Support Oncol. 2003. PMID: 15334872 Review.
Cited by
-
Eicosapentaenoic acid inhibits cell growth and triacylglycerol secretion in McA-RH7777 rat hepatoma cultures.Biochem J. 1992 Aug 15;286 ( Pt 1)(Pt 1):305-12. doi: 10.1042/bj2860305. Biochem J. 1992. PMID: 1520281 Free PMC article.
-
The role of triglyceride lipases in cancer associated cachexia.Trends Mol Med. 2013 May;19(5):292-301. doi: 10.1016/j.molmed.2013.02.006. Epub 2013 Mar 14. Trends Mol Med. 2013. PMID: 23499576 Free PMC article. Review.
-
Nutritional Interventions to Improve Cachexia Outcomes in Cancer-A Systematic Review.Medicina (Kaunas). 2022 Jul 21;58(7):966. doi: 10.3390/medicina58070966. Medicina (Kaunas). 2022. PMID: 35888685 Free PMC article.
-
Nutritional prehabilitation in head and neck cancer: a systematic review.Support Care Cancer. 2022 Nov;30(11):8831-8843. doi: 10.1007/s00520-022-07239-4. Epub 2022 Aug 1. Support Care Cancer. 2022. PMID: 35913625
-
Lipid metabolism in cancer cachexia.Br J Cancer. 1992 Jul;66(1):57-61. doi: 10.1038/bjc.1992.216. Br J Cancer. 1992. PMID: 1637677 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials